I. Tannock

Publications709
h-index113
Citations58,688
Highly Influential Citations1,720
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • J. D. de Bono
  • 792 Publications • 65,817 Citations
  • H. Scher
  • 1,137 Publications • 104,175 Citations
  • K. Fizazi
  • 1,002 Publications • 52,105 Citations
  • E. Small
  • 788 Publications • 53,203 Citations
  • Publications
  • Influence
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
TLDR
When given with prednisone, treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared with mitoxantrone plusprednisone.
View on PubMed
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
TLDR
New consensus criteria for eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone are defined, with increasing emphasis on time-to-event end points as decision aids in proceeding from phase II to phase III trials.
View on PubMed
Measuring health-related quality of life.
View on PubMed
Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis.
TLDR
A high NLR is associated with an adverse OS in many solid tumors, and its addition to established prognostic scores for clinical decision making warrants further investigation.
View on PubMed
Drug penetration in solid tumours
TLDR
The evidence that indicates that the distribution of many anticancer drugs in tumours is incomplete is summarized, and strategies that might be used either to improve drug penetration through tumour tissue or to select compounds based on their abilities to penetrate tissue are suggested, thereby increasing the therapeutic index.
View on Springer
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
TLDR
Chemotherapy with mitoxantrone and prednisone provides palliation for some patients with symptomatic hormone-resistant prostate cancer and most responding patients had an improvement in quality-of-life scales and a decrease in serum prostate-specific antigen (PSA) level.
View on PubMed
Drug resistance and the solid tumor microenvironment.
TLDR
How the tumor microenvironment may be involved in the resistance of solid tumors to chemotherapy and potential strategies to improve the effectiveness of drug treatment by modifying factors relating to the tumormicroenvironment are described.
View on PubMed
Acid pH in tumors and its potential for therapeutic exploitation.
TLDR
Measurement of pH in tissue has shown that the microenvironment in tumors is generally more acidic than in normal tissues, and acid conditions in tumors might allow the development of new and relatively specific types of therapy which are directed against mechanisms which regulate pHi under acid conditions.
View on PubMed
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
TLDR
It is confirmed that survival of men with metastatic HRPC is significantly longer after treatment with D3P than with MP, and consistent results are observed across subgroups of patients.
View on PubMed
Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study.
TLDR
Fatigue, menopausal symptoms, and cognitive dysfunction are important adverse effects of chemotherapy that improve in most patients and Hormonal treatment has minimal impact on them.
View on PubMed
...
...